All In Biotech

Drug Trial Radar · NCT00031707

Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite

Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Megestrol Acetate (Megace) Versus an N-3 Fatty Acid (EPA) Enriched Nutritional Supplement Versus Both for the Treatment of Cancer Cachexia and Anorexia

Last checked: Nov 20, 2026Latest source record: Jul 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 429 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

429

Actual

Start

Mar 2000

Primary completion

Jan 2004

Study completion Jan 2004

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); NCIC Clinical Trials Group
First posted
Aug 5, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may improve cancer-related weight loss and lack of appetite. It is not yet known whether megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a combination of both is most effective in treating cancer-related weight loss and loss of appetite. PURPOSE: Randomized phase III trial to compare the effectiveness of megestrol with or without an omega-3 fatty acid-enriched nutritional supplement to that of the omega-3 fatty acid-enriched nutritional supplement alone in treating patients who have cancer-related weight loss and lack of appetite.

Conditions

  • Anorexia
  • Cachexia

Interventions

  • eicosapentaenoic acidDietary supplement

  • megestrol acetateDrug

  • placeboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the appetite-stimulating properties (eg, patient weight, rate of weight change, and appetite)Time frame: Up to 5 years

Locations

44 sites in 2 countries. Site status is shown where the registry gives one.

  • CCOP - Scottsdale Oncology Program

    Scottsdale, Arizona

  • Mayo Clinic

    Jacksonville, Florida

  • CCOP - Illinois Oncology Research Association

    Peoria, Illinois

  • CCOP - Carle Cancer Center

    Urbana, Illinois

  • CCOP - Cedar Rapids Oncology Project

    Cedar Rapids, Iowa

  • CCOP - Iowa Oncology Research Association

    Des Moines, Iowa

  • Siouxland Hematology-Oncology

    Sioux City, Iowa

  • CCOP - Wichita

    Wichita, Kansas

  • CCOP - Ochsner

    New Orleans, Louisiana

  • CCOP - Ann Arbor Regional

    Ann Arbor, Michigan

  • CCOP - Duluth

    Duluth, Minnesota

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • CentraCare Health Plaza

    Saint Cloud, Minnesota

  • CCOP - Missouri Valley Cancer Consortium

    Omaha, Nebraska

  • Medcenter One Health System

    Bismarck, North Dakota

  • CCOP - Merit Care Hospital

    Fargo, North Dakota

  • Altru Health Systems

    Grand Forks, North Dakota

  • CCOP - Toledo Community Hospital Oncology Program

    Toledo, Ohio

  • CCOP - Geisinger Clinic and Medical Center

    Danville, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Rapid City Regional Hospital

    Rapid City, South Dakota

  • CCOP - Sioux Community Cancer Consortium

    Sioux Falls, South Dakota

  • Tom Baker Cancer Center - Calgary

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • British Columbia Cancer Agency - Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • Nanaimo Cancer Clinic

    Nanaimo, British Columbia, Canada

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada

  • Saint John Regional Hospital

    Saint John, New Brunswick, Canada

  • Newfoundland Cancer Treatment and Research Foundation

    St. John's, Newfoundland and Labrador, Canada

  • William Osler Health Centre

    Brampton, Ontario, Canada

  • Cancer Care Ontario-Hamilton Regional Cancer Centre

    Hamilton, Ontario, Canada

  • Kingston Regional Cancer Centre

    Kingston, Ontario, Canada

  • Cancer Care Ontario-London Regional Cancer Centre

    London, Ontario, Canada

  • Trillium Health Centre

    Mississauga, Ontario, Canada

  • Ottawa Regional Cancer Centre

    Ottawa, Ontario, Canada

  • Peterborough Oncology Clinic

    Peterborough, Ontario, Canada

  • Toronto Sunnybrook Regional Cancer Centre

    Toronto, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Queen Elizabeth Hospital, PEI

    Charlottetown, Prince Edward Island, Canada

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.